PE20151766A1 - Agentes quelantes de precursores de producto final de glicacion avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Info

Publication number
PE20151766A1
PE20151766A1 PE2015001994A PE2015001994A PE20151766A1 PE 20151766 A1 PE20151766 A1 PE 20151766A1 PE 2015001994 A PE2015001994 A PE 2015001994A PE 2015001994 A PE2015001994 A PE 2015001994A PE 20151766 A1 PE20151766 A1 PE 20151766A1
Authority
PE
Peru
Prior art keywords
age
precursors
end product
chelating agents
advanced glycation
Prior art date
Application number
PE2015001994A
Other languages
English (en)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20151766A1 publication Critical patent/PE20151766A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A AGENTES QUELANTES DE PRECURSORES DE PRODUCTO FINAL DE GLICACION AVANZADA (AGE) DE FORMULA (I) DONDE R1, R2, R3, R4, R5, R6, n, o Y x SON TAL COMO SE DEFINEN EN LA DESCRIPCION, LOS CUALES COMPRENDEN AMINAS SEPARADAS POR 2, 3 O 4 CARBONOS. LOS QUELANTES DE PRECURSORES DE AGE SE UNEN A DICARBONILOS DIETETICOS, UN PRECURSOR FUNDAMENTAL EN LA FORMACION DE AGE. DICHOS AGENTES QUELANTES DE PRECURSORES SE PUEDEN EMPLEAR EN COMPOSICIONES FARMACEUTICAS SIENDO UTILES PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO NEFROPATIA DIABETICA, ENFERMEDAD RENAL CRONICA, ATEROSCLEROSIS, APOPLEJIA, CATARATAS, ENFERMEDAD DE ALZHEIMER
PE2015001994A 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age) PE20151766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151766A1 true PE20151766A1 (es) 2015-12-11

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001994A PE20151766A1 (es) 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (es)
EP (1) EP2968403A1 (es)
JP (4) JP2016512830A (es)
KR (1) KR20150130492A (es)
CN (1) CN105188718A (es)
AR (1) AR095593A1 (es)
AU (2) AU2014235500A1 (es)
BR (1) BR112015023404A8 (es)
CA (1) CA2906501A1 (es)
CL (1) CL2015002624A1 (es)
CR (1) CR20150545A (es)
DO (1) DOP2015000221A (es)
EA (1) EA201591733A1 (es)
HK (1) HK1220607A1 (es)
IL (1) IL241406A0 (es)
MA (1) MA38487A1 (es)
MX (1) MX2015012843A (es)
PE (1) PE20151766A1 (es)
PH (1) PH12015502019A1 (es)
SG (2) SG11201506413PA (es)
TN (1) TN2015000390A1 (es)
TW (1) TW201521744A (es)
UY (1) UY35441A (es)
WO (1) WO2014150873A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112020003638A2 (pt) * 2017-08-31 2020-09-01 Cytosorbents Corporation redução de produtos finais de glicação avançada a partir de fluidos corporais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
PT1923064T (pt) * 2001-04-18 2017-08-23 Genzyme Corp Utilização de um aminopolímero para reduzir a glicose sérica
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
EP1753861A4 (en) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
CN105017481B (zh) * 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺

Also Published As

Publication number Publication date
SG11201506413PA (en) 2015-09-29
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
CL2015002624A1 (es) 2016-03-11
US20180265613A1 (en) 2018-09-20
AR095593A1 (es) 2015-10-28
SG10201707590XA (en) 2017-11-29
UY35441A (es) 2014-10-31
JP2016512830A (ja) 2016-05-09
KR20150130492A (ko) 2015-11-23
IL241406A0 (en) 2015-11-30
US20160024233A1 (en) 2016-01-28
MA38487A1 (fr) 2017-12-29
MX2015012843A (es) 2016-08-08
EA201591733A1 (ru) 2016-01-29
EP2968403A1 (en) 2016-01-20
JP2020055850A (ja) 2020-04-09
HK1220607A1 (zh) 2017-05-12
JP2022037143A (ja) 2022-03-08
BR112015023404A2 (pt) 2017-07-18
CA2906501A1 (en) 2014-09-25
CR20150545A (es) 2015-12-01
WO2014150873A1 (en) 2014-09-25
AU2019201259A1 (en) 2019-03-14
TW201521744A (zh) 2015-06-16
PH12015502019A1 (en) 2016-01-11
DOP2015000221A (es) 2015-12-15
AU2014235500A1 (en) 2015-11-05
BR112015023404A8 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2021009322A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
CL2016001150A1 (es) Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12017502201A1 (en) Substituted pyridines and method of use
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
PH12015502075A1 (en) Treatment of cataplexy
EA201400754A2 (ru) Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их
TN2016000022A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
EA201390381A1 (ru) Триазиноксадиазолы
MY178251A (en) New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
EA201491581A1 (ru) Везикулярные композиции
PE20151766A1 (es) Agentes quelantes de precursores de producto final de glicacion avanzada (age)
EA201591449A1 (ru) Способы получения противораковых композиций
EA201501177A1 (ru) Фармацевтические композиции
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.
WO2016039936A3 (en) Monocyclic substituted 2-pyridinone antibacterial compounds
TN2013000089A1 (en) Triazine-oxadiazoles